<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Mao C</submitter><funding>NCI NIH HHS</funding><pagination>586-590</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC8895686</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>593(7860)</volume><pubmed_abstract>Ferroptosis, a form of regulated cell death that is induced by excessive lipid peroxidation, is a key tumour suppression mechanism&lt;sup>1-4&lt;/sup>. Glutathione peroxidase 4 (GPX4)&lt;sup>5,6&lt;/sup> and ferroptosis suppressor protein 1 (FSP1)&lt;sup>7,8&lt;/sup> constitute two major ferroptosis defence systems. Here we show that treatment of cancer cells with GPX4 inhibitors results in acute depletion of N-carbamoyl-L-aspartate, a pyrimidine biosynthesis intermediate, with concomitant accumulation of uridine. Supplementation with dihydroorotate or orotate-the substrate and product of dihydroorotate dehydrogenase (DHODH)-attenuates or potentiates ferroptosis induced by inhibition of GPX4, respectively, and these effects are particularly pronounced in cancer cells with low expression of GPX4 (GPX4&lt;sup>lo</pubmed_abstract><journal>Nature</journal><pubmed_title>DHODH-mediated ferroptosis defence is a targetable vulnerability in cancer.</pubmed_title><pmcid>PMC8895686</pmcid><funding_grant_id>P50 CA070907</funding_grant_id><funding_grant_id>P30 CA016672</funding_grant_id><funding_grant_id>U54 CA224065</funding_grant_id><funding_grant_id>R01 CA247992</funding_grant_id><funding_grant_id>R01 CA244144</funding_grant_id><funding_grant_id>R01 CA181196</funding_grant_id><funding_grant_id>R01 CA190370</funding_grant_id><pubmed_authors>Gan B</pubmed_authors><pubmed_authors>Lei G</pubmed_authors><pubmed_authors>Lee H</pubmed_authors><pubmed_authors>Fang B</pubmed_authors><pubmed_authors>Yan Y</pubmed_authors><pubmed_authors>Olszewski K</pubmed_authors><pubmed_authors>Liu X</pubmed_authors><pubmed_authors>Poyurovsky MV</pubmed_authors><pubmed_authors>Mao C</pubmed_authors><pubmed_authors>Zhang Y</pubmed_authors><pubmed_authors>Wu S</pubmed_authors><pubmed_authors>Koppula P</pubmed_authors><pubmed_authors>Zhuang L</pubmed_authors></additional><is_claimable>false</is_claimable><name>DHODH-mediated ferroptosis defence is a targetable vulnerability in cancer.</name><description>Ferroptosis, a form of regulated cell death that is induced by excessive lipid peroxidation, is a key tumour suppression mechanism&lt;sup>1-4&lt;/sup>. Glutathione peroxidase 4 (GPX4)&lt;sup>5,6&lt;/sup> and ferroptosis suppressor protein 1 (FSP1)&lt;sup>7,8&lt;/sup> constitute two major ferroptosis defence systems. Here we show that treatment of cancer cells with GPX4 inhibitors results in acute depletion of N-carbamoyl-L-aspartate, a pyrimidine biosynthesis intermediate, with concomitant accumulation of uridine. Supplementation with dihydroorotate or orotate-the substrate and product of dihydroorotate dehydrogenase (DHODH)-attenuates or potentiates ferroptosis induced by inhibition of GPX4, respectively, and these effects are particularly pronounced in cancer cells with low expression of GPX4 (GPX4&lt;sup>lo</description><dates><release>2021-01-01T00:00:00Z</release><publication>2021 May</publication><modification>2026-06-03T10:22:35.557Z</modification><creation>2025-02-18T23:36:42.878Z</creation></dates><accession>S-EPMC8895686</accession><cross_references><pubmed>33981038</pubmed><doi>10.1038/s41586-021-03539-7</doi></cross_references></HashMap>